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Reduction o f Epidermal Abnormalities and 
Inflammatory Changes in Psoriatic Plaques During 
Treatment With Vitamin D3 Analogs
Peter C. M. van de Kerkhof
Department of Dermatology, University of Nijmegen, Nijmegen, The Netherlands
V itam in  D 3 analogs in terfere w ith various aspects o f  
epiderm al grow th , in flam m ation , and cellular differ­
entiation* M ost data are derived from  in vitvo studies. 
In the present rev iew , the in vivo effects o f  vitam in D 3 
analogues on the psoriatic p laque are discussed. Cal­
cipotrio l, taca lc ito l, and calcitrio l in  ointm ent m od­
ulate aspects o f  ep iderm al growth* differentiation, 
and in flam m ation . Im m unohistochem ical studies 
su ggest that the in flam m atory  changes m ight be 
m ore expressed after trea tm en t w ith  calcitriol and 
tacalcitoL  Flow  cytom etric  quantification o f  the per­
centage o f  cells in  SG2M phase and o f  keratin 10 -  
p ositive cells revea led  that ca lc ip otrio l reduced both 
ind ices sign ificantly  during treatm ent o f  psoriatic 
plaques. P low  cytom etric  analysis o f  epidermal cell
I
n the last decade, vitamin D 3 analogs liave become an 
important approach in the treatment o f psoriasis. Calcipot­
riol is available as a routine treatment in many countries 
(Binderup and Kragballe, 1992). In Japan, tacalcitol (la , 
24-dihydroxyvitamin D 3) is a first line of treatment for 
psoriasis (Nishinura et a l , 1993). Calcitriol (la,25-dihydroxyvita- 
min D3) is the naturally occurring, active vitamin D3 and has been 
investigated with respect to its antipsoriatic efficacy and safety 
(Langner et al, 1992).
The aim of the present review is to evaluate the actions of 
calcipotriol, tacalcitol, and calcitriol on psoriatic skin during topical 
treatment.
VITAMIN D 3 ANALOGS INHIBIT EPIDERMAL 
PROLIFERATION, ENHANCE NORMAL 
KERATINIZATION, AND MODULATE INFLAMMATION
Calcipotriol, calcitriol, and tacalcitol bind to the vitamin D receptor 
(VDR), and the complex binds to vitamin D response elements 
within promoter regions o f vitamin D response genes (Ozone et al, 
1991). V D R belongs to the steroid receptor superfamily together 
with the receptors for retinoids, estrogen, thyroxine, and glucocor- 
ticosteroids. Evidence is accumulating that the receptors within this 
family do not act in isolation, but interact. As such, the heterodimer 
formation of V D R  and the R X R -a  receptor is important because
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Abbreviations; TP3, TO-PRO-3 iodide; VDR, vitamin D receptor.
suspensions using triple labeling  for epiderm al pro­
liferation , expression o f  keratin 10, and vim entin  
perm its a quantitative assessm ent o f  D N A  synthesis 
selectively  in  the basal cells o f  the epiderm is, an 
estim ation  o f  the distribution o f  the basal and supra- 
basal com partm ents, and a quantification o f  the dis­
tribution o f  m esenchym al and nonm esenchym al cells. 
U sing this approach, the in terference o f  tacalcitol 
w ith grow th control o f  basal cells was dem onstrated. 
R em arkably, recom partm entalization  o f  basal and 
suprabasal cells and m esenchym al and nonm esenchy­
m al cells proved to be inconspicuous during this 
treatm ent. Key wovds: calcitriol/calcipotriol/tacalcitol. 
Tournal o f  Investigative Dermatology Symposium Proceed­
ings 1 :7 8 -8 1 , 1996
the heterodimer exerts a more potent binding with vitamin D 
response elements compared with VDR alone (Kliewer et nl, 1992).
In addition to these nuclear mechanisms, vitamin D3 analogs 
have a direct effect on calcium entry. Indeed at physiologic 
concentrations, calcitriol lias been shown to enhance calcium entry 
into keratinocytes (Brittener et al, 1991).
Either via nuclear mechanisms or by increased entry of calcium 
into the cell, vitamin D3 enhances the production of inositol 
trisphosphate and 1,2-diacylglycerol (MacLaughlin et al, 1990). 
Another important effect of vitamin D3 analogs in cell signaling is 
the translocation of protein kinase C from the cytosolic to the 
membrane position (Yada et al, 1989).
At the cellular level, vitamin D3 analogs have been shown to 
inhibit proliferation of keratinocytes and to enhance cornified 
envelope formation (Binderup and Bramm, 1988; Kragballe and 
Wildfang, 1990). At the molecular level, vitamin D3 analogs 
enhance transglutaminase activity, which is a crucial enzyme for 
cornified envelope formation (Hosomi et al, 1983; Lee et al, 1989; 
Matsunaga et a l , 1990). In contrast to retinoids, vitamin D3 analogs 
do not modulate the transcription of keratin genes. These com­
pounds specifically interfere with the last step of differentiation 
(Regnier and Darmon, 1,991).
Vitamin D3 analogs have diverse effects on inflammation control. 
Interleukin (IL)-1—induced T-lymphocyte proliferation is inhibited 
by active vitamin D3 (Tsoukas et al, 1984). Production of IL-2 and 
IL-6 by T  lymphocytes and accumulation of mRNA for IL-2, 
interferon-gamma, and granulocyte-macrophage colony-stimulat­
ing factor increase in the T  lymphocyte after incubation with 
calcitriol (Tsoukas et a l , 1984; Gupta et al> 1989; Hustmyer et al, 
1991; Lemire, 1992). Macrophages are activated by calcitriol, and
1087-0024/9610 .50  • Copyright © 1996 by The Society for Investigative Dermatology, Inc
78
VOL. 1, NO. 1, APRIL 1996 VITAMIN D3 AND T H E  PSOIUATIC LESION 79
Table I. M onoclonal Antibodies Used for the 
Im m unohistochem ical Assessments"
Cell Biologic Feature Antibody
Recruitment of cycling cells Ki-6 7
Kem tin 16 expression Ks 8.12
Involucrin Mon-150
Filaggrin Anti-filaggrin (BT 576)
Transglutaminase I Anti-TG-ase I (IgG2il)
Pan T cells T 11
Polymorphonuclear leukocytes An ti-ela stase
Monocytes (CD 14) W T 14
Langcrhans cells OKT 6
0 The immunohistochemical procedures have been described before (de Jong and 
van de Kerkhof, 1991; Gerritsen ct of, 1993, 1994, 1995).
the interferon-gamma-induced expression of human leukocyte 
antigen-D on keratinocytes is inhibited by calcitriol (Lehman and 
Gray, 1984; Petrini ct al, 1991; Tone et al, 1991; Oberg et al, 1993). 
Archidonic acid release and migration of polymorphonuclear leu­
kocytes (PMN) are inhibited by vitamin D3 analogs (Tanaka et al, 
1988).
VITAMIN D3 ANALOGS ARE CLINICALLY EFFECTIVE IN 
CHRONIC PLAQUE PSORIASIS, PUSTULAR PSORIASIS,
AND ICHTHYOSES
Based on the in vitro observations, it is feasible that calcipotriol, 
tacalcitol, and calcitriol are effective in skin disorders characterized 
by epidermal hyperproliferation, abnormal keratinization, and in­
flammation. Indeed, the therapeutic efficacy of active vitamin D3 is. 
not restricted to chronic plaque psoriasis, but also affects pustular 
psoriasis (Berth Jones et al, 1992). Active vitamin D 3 lias proved 
effective in some disorders of keratinization (Kragballe et al, 1995).
REDUCTION OF IMMUNOHISTOCHEMICAL CHANGES
DURING TREATMENT
Three clinical studies were carried out in patients with chronic 
plaque psoriasis to assess the effect of twice-daily applications of 
calcipotriol (50 ¡x g/g) in ointment, once-daily applications of tacalcitol 
(4 ¡Jig/g) in ointment, and twice-daily applications of calcitriol (3 
/¿g/g) in ointment (de Jong et al, 1991; Gerritsen et aU 1993, 1994, 
1995). In previous dose-response studies, these concentrations proved 
to provide optimal clinical efficacy. In total, eight pa dents were 
included for treatment with calcipotriol, ten patients for treatment 
with calcitriol, and ten patients for treatment with tacalcitol in 
ointment. Before treatment and at various times, biopsy specimens 
were taken and processed for immunohistochemical assessment.
The immunohistochemical methods have been described before 
(de Jong et al, 1991; Gerritsen et al, 1993). In brief, samples were 
snap-frozen in liquid nitrogen, and consecutive sections were cut. 
Epidermal growth, differentiation, and inflammation characteristics 
were analyzed using an indirect peroxidase technique. Table I 
summarizes the monoclonal antibodies used in the studies.
Although the concentrations of active vitamin D3 analogs used in 
the treatments were different, the clinical improvement was com­
parable. Approximately a 50% reduction of the psoriasis area 
severity index was achieved for all three analogs (Gerritsen et al,
1994, 1995).
The maximum observation period for calcipotriol ointment was
12 wk (de Jong et at, 1991). After 2 wk of treatment with 
calcipotriol ointment, a significant decrease in the number o f 
cycling epidermal cells (Ki-67-positive nuclei) was observed. Dur­
ing the subsequent observation period, the number o f Ki-67- 
positive nuclei showed only a modest reduction beyond that 
reached after 2 wk o f treatment. Keratin 16 (Ks 8.12 binding of the 
suprabasal compartment o f the epidermis) tended to decrease 
between 4 and 8 wk o f treatment. After 1 wk of treatment, only 
small micro abscesses of PMN were observed, and after 4 wk o f 
treatment, no microabscesses were observed at all. The accumula­
tion o f  T cells showed only a small reduction in the 12-wk 
treatment period, reaching borderline significance after 4  wk. The 
accumulation of monocytes and macrophages did no t show a 
significant modulation during calcipotriol treatment.
The maximum observation period for calcitriol treatment was 4 
w k (Gerritsen et al, 1993). During this treatment period, the 
maximum reduction o f the num ber o f  Ki-6 7-positive epidermal 
nuclei was observed after 4 w k o f treatment. In this study, the 
numbers o f  involucrin-positive and transglutaminase-I-positive 
cells decreased, and the num ber o f filaggrin-positive cells increased. 
Pan T cells and PMN decreased markedly during the observation 
period.
The maximum observation period for tacalcitol treatment was 8 
wk (Gerritsen et al, 1994, 1995). During this interval, the numbers 
of Ki-67-positive nuclei and the involucrin-, keratin-16-, and 
transglutaminase-positive cell layers had diminished substantially, 
whereas the number of filaggrin-positive cell layers had increased, 
Tacalcitol had a remarkable effect on the num ber of PM N, T cells, 
and monocytes in the dermis and epidermis of the psoriatic lesion. 
In contrast, the ointment w ithout tacalcitol had no significant effect 
on these markers, apart from a reduction in the num ber o f 
Ki-67-positive nuclei.
These immunohistochemical studies suggest that the three vita­
min D3 analogs have an effect on epidermal growth, keratinization, 
and cutaneous inflammation (T able II). The reduction o f  the 
inflammatory infiltrate was most pronounced after treatment w ith 
tacalcitol. Definitive conclusions on the relative potencies of these 
analogs require comparative studies.
In various centers, the in v ivo  effects o f vitamin D3 analogs have 
been studied. On the one hand, these studies suggest a reduction 
o f keratin-16- and keratin-17-positive cells and normalization o f 
keratin-5- and keratin-10-positive cells, with only modest changes 
o f the immune system (Verburgh et. al, 1989; Holland et aU 1990; 
Berth Jones et al, 1991; de Jong et al, 1991). One study suggested, 
however, that calcipotriol treatment causes a reduction o f  helper T  
cells with a relative persistance o f  epidermal phenomena (Malet et 
al> 1990). In another study, it was shown that calcipotriol treatment 
reduced IL-6 staining without altering tum or necrosis factor-a 
staining (Oxholm et al, 1989). Light and electron microscopic 
investigations showed that tacalcitol treatment induced a normal 
keratin pattern and the reappearance o f  normal keratohyalin gran­
ules (Ueda et al, 1989).
The general pattern o f  the immunohistochemical response is a 
pronounced reduction o f  epidermal proliferation and the accumu­
lation o f  PMN. Other topical treatments such as corticosteroids (de 
Jong et al, 1995) and dithranol (de Jong and van de Kerkhof, 1992) 
were shown to have a similar in v ivo  response: the reduction o f 
epidermal proliferation and the accumulation o f P M N  as a non­
specific effect- The reduction o f  PMN, T  cells, and monocytes,
Table II. R ed u ction  o f  E piderm al P roliferation  and  
M odulation o f  K eratin ization  and In flam m ation  D u rin g  
T reatm ent W ith  V itam in  D 3 A n alogs*1
Ciilcipotriol Calcitriol Tacalcitol
(50 Mg/g (3 Mg/g (4 ¿Ag/g
Twice Daily) Twice Daily) Oncc Daily)
Ki-67 u u u
Keratin 16 ND i
Involucrin ND i i
Filaggrin ND s S
Transglutaminase ND y \ /
Polymorphonuclear leukocytes ü u
Pan T cells i 1
Monocytes — ND 1
Langcrhans cells ND
" Quantification o f  the responses lias bcien described before (de Jong and van de 
Kerkhof, 1991; Gerritsen ct al, 1993, 1994, 1995). Abbreviations: = , no modulation;
slight decrease after treatment; JJ, marked decrease after treatment; |  , slight 
increase after treatment; N D , not done.
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however, was relatively more expressed during treatment with 
calcitriol and tacalcitol than with calcipotriol.
The antiproliferative action and the inhibition of PMN function­
ing are observed both in intro and in v ivo .  In contrast to the 
activation o f monocytes in v itro , tacalcitol induced a reduction of 
the accumulation o f  monocytes in the psoriatic plaques. And in 
contrast to the substantial inhibition of T-cell functioning in vitro, 
these cells tended to persist during treatment with vitamin D3 
analogs. In contrast to enhancement o f  transglutaminase I activity in 
vitro, during treatment with vitamin D3 analogs the number of 
transgiutaminase-I—positive cell layers decreased.
To elucidate further the in vivo action profile o f vitamin D3 
analogues, quantitative comparative studies are required,
FLOW  CYTOM ETRIC QUANTIFICATION OF EPIDEBJV1AL
CHANGES D U RIN G  TREATMENT
To quantify epidermal hyperproliferation in the psoriatic plaque 
before and during treatment with calcipotriol and betamethasone, 
flow cytometric assessment was carried out o f DNA distribution 
and keratin 16 expression (de Mare et al, 1990). In this study, a 
group o f 20 patients with chronic plaque psoriasis were treated 
twice daily with calcipotriol (50 /x§^g) h1 ointment and betametha­
sone in ointment in a double-blind trial with a left-right compari­
son. Before treatment and after a treatment period of 6 wk, 
razor-blade biopsy specimens (0.5 mm thick, 4 mm in diameter) 
were taken from two lesions at both sides. Epidermal cell suspen­
sions were prepared using a trypsinization procedure, as described 
previously (Bauer cf al, 1980). To assess keratin 16 expression, we 
incubated the cell suspensions with the monoclonal antibody Ks 
8.12 and fluorescein isothiocyanate (FITC)-conjugated anti-mouse 
IgG as second antibody (de Mare ct al, 1990). Propidium iodide was 
added to measure relative DNA content per cell (de Mare et al, 
1990). Five thousand cells of each sample were analyzed using an 
Ortho 50H flow cytometer equipped with a 5-W  argon laser tuned 
at 488 ran. Both treatments induced similar reductions of these 
indices. The values, however, were still well above the normal 
ranges (percentage Ks 8.12 cells: 1.8 — 1.0 [mean ± SEM] [van Erp 
et nl, 1989] and percentage cells in SG2M phase: 4.0 ±  0.7 [Bauer 
et ol, 1981]).
Although this approach permits quantification of proliferation 
characteristics in epidermal cells, the methodology is complicated 
by the fact that suprabasal cells and mesenchymal cells are not 
excluded from the assessment.
Recently, a new methodology was developed using a triple 
labeling approach. Per-cell DNA content was measured using the 
new DNA stain TO -PR O -3 iodide (TP3); anti-vimentin was used 
to identify all nonkeratinocytes (infiltrate cells and other mesen­
chymal cells); RKSE 60 staining was carried out to assess keratin 10 
expression, which indicates whether a cell belongs to the suprabasal 
cell population. Cell suspensions were prepared as described be­
fore, and the staining procedures have been described previously 
(Bauer and Boezeman, 1983; van Hooijdonk et al, 1995). The 
second step of the indirect immunofluorescent staining was per­
formed with monoclonal goat antibodies against mouse IgG1 and 
IgG2a, conjugated to phycoerythrin and fluorescein-isothiocyanate 
(FITC), to assess RKSE 60 binding and anti-vimentin binding, 
respectively. Phycoerythrin and FITC were excited with an air- 
cooled argon laser (633 nm), and TP3 was excited with an HeNe 
laser (488 nm). After electron compensation for spectral overlap, 
which was minimal in the case o f TPV fluorescence was measured 
using band-pass filters at 525 nm (green FITC), 575 nm (orange, 
phycoerythrin), and 675 nm (red, TP3). The ratio of area to peak of 
the red signal was used to discriminate between doublets of diploid 
cells and real tetraploid cells (Bauer and Boezeman, 1983). After 
setting the appropriate gates with the Elite software percentages and 
with the aid o f Multicycle software, the percentages of vimentin- 
and keratin-10-positive cells and the percentage of cells in SG2M 
phase were calculated. From these data, the percentage of cells in 
SG2M phase within the pure basal cell population was calculated.
In total, 20 patients participated in a left-right comparative study
between tacalcitol (4 / ¿ g / g )  in ointment and the ointment base only 
(Glade et al, 1995). Applications were done once daily. Razor-blade 
biopsy specimens were taken before treatment and after 8 wk of 
treatment from two lesions at both sides. Cell suspensions were 
prepared, and triple-label flow cytometric assessment was carried 
out according to the methods described above. The sides treated 
with tacalcitol showed a mean reduction of the psoriasis area 
severity score of 48%. The psoriasis area severity score of the lesions 
treated with placebo ointment was decreased by 28%.
In the psoriatic lesions before tacalcitol treatment, the percentage 
of basal cells in SG2M phase was 20.0 ± 1.9% (mean ±  SEM); after
8 wk o f treatment, the percentage was reduced to 13.2 ±  1.1%. 
This reduction was statistically significant (p ^  0.01). At the 
placebo-treated sides, the pretreatment value was 17.8 ±  1.8%, and 
the value after 8 wk o f placebo treatment was 15.1 ±  1.2%.
The pronounced reduction of this cell-cycle kinetic marker 
during tacalcitol treatment illustrates the potent effect of tacalcitol 
on epidermal hyperproliferation in vivo. Triple-label flow cytometry 
has proved to be an adequate tool to restrict the analysis of indices 
for epidermal proliferation to the basal cells, even within a popu­
lation as heterogeneous and complex as the inflamed epidermis of 
the psoriatic lesion.
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